Report ID: SQMIG15E2332
Report ID:
SQMIG15E2332 |
Region:
Global |
Published Date: February, 2024
Pages:
221
|
Tables:
66 |
Figures:
65
Ethyl Pyruvate Market size was valued at USD 2.16 billion in 2019 and is poised to grow from USD 2.3 billion in 2023 to USD 3.66 billion by 2031, growing at a CAGR of 6.7% in the forecast period (2024-2031).
Ethyl Pyruvate is a new anti-inflammatory drug used to treat severe inflammatory disorders. In animal models of disease such as pancreatitis, ischemia-reperfusion injury, sepsis, kidney injury, and endotoxemia, CTI-01 displays significant anti-inflammatory and tissue protective effects. The increase in R&D activities to investigate the application of Ethyl pyruvate to treat chronic illnesses in humans is expected to fuel market growth. Researchers are attempting to determine the anticancer activity of Ethyl pyruvate in non-small cell lung cancer (NSCLC) cells and to elucidate the underlying mechanism. It inhibits non-small cell lung cancer cell proliferation, invasion, and migration while inducing apoptosis via the HMGB1/RAGE axis and the NFB/STAT3 pathway.
US Ethyl Pyruvate Market is poised to grow at a sustainable CAGR for the next forecast year.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONEthyl Pyruvate Market size was valued at USD 2.16 billion in 2019 and is poised to grow from USD 2.3 billion in 2023 to USD 3.66 billion by 2031, growing at a CAGR of 6.7% in the forecast period (2024-2031).
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG15E2332